Ranked #1,636 of 8,699 institutional investors
Nextech Invest Ltd.
Zurich, V8
$1.78B
US stock portfolio at live prices · today −$7.9M (−0.44%)
Market closed. Prices as of Nov 20, 8:41 AM ET
- Value at quarter end (Q3 2026)
- $2.23B
- Change from Q2 2026
- +$125.0M (+5.93%)
- Positions
- 18 · 4 new, 1 sold out
- Filed
- Nov 16, 2026
Holdings
Q3 2026 13F, live pricesRVMD 68.1%PBLS 7.24%RLAY 6.06%TYRA 3.82%ORIC 3.10%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | 7,601,087 | $1.21B | 68.1% | Unchanged |
| PBLS Parabilis Medicines, Inc. | 4,663,176 | $129M | 7.24% | Unchanged |
| RLAY Relay Therapeutics, Inc. | 6,776,506 | $108M | 6.06% | Unchanged |
| TYRA Tyra Biosciences, Inc. | 3,447,482 | $68.0M | 3.82% | Reduced −3% |
| ORIC ORIC Pharmaceuticals, Inc. | 7,162,637 | $55.2M | 3.10% | Unchanged |
| SLN Silence Therapeutics plc | 1,693,140 | $33.5M | 1.89% | Added +78% |
| KYMR Kymera Therapeutics, Inc. | 278,896 | $33.3M | 1.87% | Unchanged |
| ZYME Zymeworks Inc. | 1,113,946 | $29.9M | 1.68% | Unchanged |
| ATTO Attovia Therapeutics, Inc. | 1,835,139 | $28.6M | 1.61% | New |
| ETRA Electra Therapeutics, Inc. | 2,636,225 | $23.6M | 1.32% | New |
| ALMS Alumis Inc. | 4,550,998 | $19.7M | 1.11% | Added +29% |
| CTMX CytomX Therapeutics, Inc. | 4,449,932 | $9.1M | 0.51% | Unchanged |
| BRVE Braveheart Bio, Inc. | 416,700 | $8.0M | 0.45% | New |
| GLUE Monte Rosa Therapeutics, Inc. | 761,153 | $6.8M | 0.38% | Unchanged |
| AVTX Avalo Therapeutics, Inc. | 766,000 | $5.2M | 0.29% | New |
| CRVS Corvus Pharmaceuticals, Inc. | 450,000 | $4.5M | 0.25% | Unchanged |
| ENGN enGene Therapeutics Inc. | 2,324,943 | $4.1M | 0.23% | Unchanged |
| CNTX Context Therapeutics Inc. | 7,419,355 | $1.3M | <0.1% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| ARVN Arvinas, Inc. | 1,122,713 | $7.6M |